Schedule 13D ownership disclosure

Spyre Therapeutics Inc

Common Stock, $0.0001 par value · CUSIP: 00773J202

Event date: 2025-10-15

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Fairmount Funds Management LLCReported CIK 0001802528

    Shares: 7,272,341.00 · Class: 8.99%

  • Fairmount Healthcare Fund II L.P.Reported CIK 0001769651

    Shares: 7,272,341.00 · Class: 8.99%

  • Peter Evan HarwinReported CIK 0001663607

    Shares: 8,106,882.00 · Class: 9.99%

  • Tomas KiselakReported CIK 0001830177

    Shares: 8,106,882.00 · Class: 9.99%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-100449
Form type
SCHEDULE 13D/A
Filer
Fairmount Funds Management LLC
CIK
CIK 1802528
Filed
Oct 17, 2025
Reporting period
Oct 15, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub